Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Latest From Andrew McConaghie
Roche will suffer a hangover from its COVID-19 successes this year as revenues stagnate and its future strategy is yet to be laid out by incoming CEO Thomas Schinecker.
Having outperformed in 2022, GSK is gearing up for key regulatory and market access decisions on its RSV vaccine, but is confident it holds superior data compared with rival Pfizer.
Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.
Eisai has spent 25 years looking for a breakthrough in Alzheimer’s and warns that healthcare systems need to undergo a major shift to accommodate its breakthrough drug.
Interest in longevity and anti-aging is gathering momentum, and Pfizer has dipped its toe in the water with an early-stage drug discovery partnership.
After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.